Viracta Therapeutics names Darrel Cohen as CMO
San Diego, USA-based cancer focussed biotech Viracta Therapeutics (Nasdaq: VIRX) today announced the appointment of Dr Darrel Cohen, as chief medical officer (CMO), with immediate effect.
Most recently, Dr Cohen was CMO of cell therapy at Athenex. Prior to this, Dr Cohen was CMO at Biosight Pharmaceuticals and head of clinical development at EUSA Pharma.
In his 25 year-long career in pharma, he has also held leadership positions of increasing responsibility at Pharmacia, Sanofi (Euronext: SAN), and Pfizer (NYSE: PFE), including vice president of late-phase clinical development at Pfizer Oncology where he was involved in multiple successful regulatory submissions of new targeted cancer drugs such as Sutent (sunitinib), Xalkori (crizotinib) and Ibrance (palbociclib).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze